• Some cancers, though, are armored against taxanes: Their cell membranes carry a multiple-drug-resistance pump that identifies taxanes as a threat and pumps them out before they can infiltrate the cell.

    FORBES: Taxol's Next Stand

  • An initial human test of the combo--chemotherapy drug idarubicin and Millennium Pharmaceuticals' multiple myeloma drug Velcade--is under way at the University of Kentucky.

    FORBES: On The Cover/Top Stories

  • Guidant, meanwhile, has suffered multiple setbacks in its drug-coated stent program, and is now far behind its competitors.

    FORBES: A Big Win For Johnson & Johnson

  • Shares in Biogen Idec dipped 2.7% not only because the Food and Drug Administration said it would take an extra three months to review its key multiple sclerosis drug, BG-12, but because an Abbott Laboratories kidney cancer medicine that in some ways works similarly to BG-12 failed.

    FORBES: Biogen Says Its FDA Delay Unrelated To Abbott's Failed Medicine

  • Tysabri, the multiple sclerosis drug made by Biogen-Idec and Elan, was pulled from the market for increasing the risk of deadly brain infection.

    FORBES: The End Of Drug Withdrawals?

  • Drug development is a costly and time-consuming process, requiring multiple rounds of FDA trials before a drug can be approved.

    FORBES: Can Non-Profit Drug Companies Cure Diseases of Poverty?

  • The reason: Biogen's (nasdaq: BIIB - news - people ) top-selling drug was another multiple sclerosis drug, Avonex.

    FORBES: Biogen Idec Hits A Nerve

  • Lofty expectations for its multiple sclerosis drug Antegren, to be co-marketed with Biogen Idec, have caused shares to quadruple this year.

    FORBES: Elan, ImClone Lose, Celgene Wins

  • After one death due to an apparent side effect, Biogen (nasdaq: BIIB - news - people ) and partner Elan (nyse: ELN - news - people ) pulled their multiple sclerosis drug Tysabri, which had been approved with rapid speed by the Food and Drug Administration only four months before.

    FORBES: Safety Vs. Efficacy

  • When the data are good enough, the FDA sometimes approves a drug based on these trials, as happened recently with Velcade, a Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) drug that treats multiple myeloma.

    FORBES: Celgene Aims For Fast FDA Approval

  • Take Millennium Pharmaceuticals (nasdaq: MLNM - news - people ), which makes the multiple myeloma drug Velcade .

    FORBES: Big Pharma Could Hog Biotech's Spotlight

  • At the American Society of Hematology in Philadelphia last week, Millennium presented data showing its cancer drug Velcade beats back multiple myeloma in one-third of patients who had failed other therapies.

    FORBES: Genomics Revolution Actually Happens

  • Other medicines, including multiple myeloma drug Velcade, from Millennium (nasdaq: MLNM - news - people ), and rheumatoid arthritis medicine Enbrel, from Amgen (nasdaq: AMGN - news - people ).

    FORBES: Patenting Gravity?

  • What NICE hasn't considered is the long term saving of keeping people with multiple-sclerosis in work and off benefits as a result of offering a drug which could control the relapses which can cause patients to go blind and leave them paralysed.

    BBC: Beta interferon: Rights and wrongs

  • Giusti founded the Multiple Myeloma Research Foundation in 1998 with the goal of using her drug industry know-how to get treatments developed.

    FORBES: Magazine Article

  • Warrell says that Erbitux's troubles validate his more conservative approach to testing Genta's Genasense drug, now in final-stage testing for melanoma, lymphoma and multiple myeloma.

    FORBES: Magazine Article

  • The U.S. Food and Drug Administration has only approved it for one-time use, rather than multiple uses.

    WSJ: Panel Pushes Vaccine for Pregnant Women

  • However, he said it would almost certainly need to be a vaccine combining multiple "Achilles heels" - in the same way that HIV therapies are a combination of drug treatments.

    BBC: Body's anti-HIV 'training manual' offers vaccine hopes

  • For Schering, which has been making strides into biotech and cancer treatment with a treatment for multiple sclerosis and Campath, a cancer drug licensed from Ilex Oncology (nasdaq: ILXO - news - people ), it is a strategic step forward.

    FORBES: Schering AG Makes Biotech Strides

  • Scott Johnson, a 52-year-old multiple sclerosis patient who served as chief executive of three startups, is influencing the direction of early drug research for his disease.

    FORBES: Magazine Article

  • The Multiple Myeloma Research Foundation is working with 30 drugs, up from none in 2000, and just recruited a cancer-drug executive from Bayer to help run its effort.

    FORBES: Magazine Article

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定